P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE

Bibliographic Details
Main Authors:	C. Harrison, J. Mascarenhas, P. Abraham, J. A. Nadal, A. Balanean, A. McBride, J. K. Kish, D. Liassou, B. A. Feinberg, A. T. Gerds
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847096.24450.eb

Similar Items

P1060: REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE
by: J. Mascarenhas, et al.
Published: (2022-06-01)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
by: V. Gupta, et al.
Published: (2022-06-01)

P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION
by: F. Passamonti, et al.
Published: (2022-06-01)

P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
by: P. Abraham, et al.
Published: (2022-06-01)

P1059: COMPARATIVE EFFICACY OF FEDRATINIB AND PACRITINIB FOR THE TREATMENT OF MYELOFIBROSIS IN PATIENTS WITH LOW PLATELET COUNTS: A SIMULATED TREATMENT COMPARISON STUDY
by: G. Tremblay, et al.
Published: (2022-06-01)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
by: Claire N. Harrison, et al.
Published: (2021-05-01)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
by: C. Harrison, et al.
Published: (2022-06-01)

Practical management of patients with myelofibrosis receiving ruxolitinib.
by: Harrison, C, et al.
Published: (2013)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
by: Naseema Gangat, et al.
Published: (2023-01-01)

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
by: Claire Harrison
Published: (2015-04-01)

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
by: V. Gupta, et al.
Published: (2022-06-01)

P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS
by: Danny Jeyaraju, et al.
Published: (2023-08-01)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
by: Srdan Verstovsek, et al.
Published: (2023-07-01)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
by: Francesca Palandri, et al.
Published: (2023-08-01)

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
by: J.-J. Kiladjian, et al.
Published: (2022-06-01)

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
by: O'Sullivan, JM, et al.
Published: (2023)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
by: Lucia Masarova, et al.
Published: (2023-08-01)

Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data
by: Adrian Duek, et al.
Published: (2025-01-01)

S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
by: Rosa Ayala, et al.
Published: (2023-08-01)

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
by: David M. Ross, et al.
Published: (2021-01-01)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
by: Harrison, C, et al.
Published: (2016)

Hemostasis in patients with primary myelofibrosis treated with ruxolitinib
by: O. G. Golovina, et al.
Published: (2024-11-01)

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
by: Naval Daver, et al.
Published: (2015-08-01)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
by: Jack W Singer, et al.
Published: (2019-01-01)

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib
by: Ruben Mesa, et al.
Published: (2023-06-01)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
by: F. Palandri, et al.
Published: (2022-06-01)

S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY
by: J. Mascarenhas, et al.
Published: (2022-06-01)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
by: Maheen Z. Abidi, et al.
Published: (2016-01-01)

Unusual cause of dyspnea in patient with Myelofibrosis: The Ruxolitinib lung
by: Antoine El Kik, et al.
Published: (2024-01-01)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
by: Sunny Sandhu, et al.
Published: (2022-01-01)

The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis
by: Robert Peter Gale, et al.
Published: (2024-07-01)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
by: P. Harrington, et al.
Published: (2022-06-01)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
by: Claire Harrison, et al.
Published: (2022-08-01)

A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis
by: Tim Kong, et al.
Published: (2024-03-01)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
by: McIlroy, G, et al.
Published: (2025)

Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era
by: Yosuke Okada, et al.
Published: (2024-06-01)

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
by: Vikas Gupta, et al.
Published: (2016-12-01)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
by: Graham McIlroy, et al.
Published: (2025-01-01)

P1044: REAL-WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA
by: J. Mei, et al.
Published: (2022-06-01)

Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study
by: Gupta, V, et al.
Published: (2018)